Identification of coinfections by viral and bacterial pathogens in COVID-19 hospitalized patients in Peru: molecular diagnosis and clinical characteristics

• Autores: Martins Luna, Johanna Elizabeth, Pérez-Lazo, Giancarlo, Silva-Caso, Wilmer, Valle-Mendoza, Juana del, Morales-Moreno, Adriana, Ballena-López, José, Soto-Febres, Fernando, Carrillo-Ng, Hugo, Valle, Luís J. del, Kym, Sungmin, Aguilar-Luis, Miguel Angel, Peña-Tuesta, Issac, Tinco-Valdez, Carmen, Illescas, Luis Ricardo
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Universidad Tecnológica del Perú
• Repositorio: UTP-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.utp.edu.pe:20.500.12867/5117
• Enlace del recurso: https://hdl.handle.net/20.500.12867/5117; https://doi.org/10.3390/antibiotics10111358
• Nivel de acceso: acceso abierto
• Materia: Coinfections; COVID-19; Antibiotics; https://purl.org/pe-repo/ocde/ford#3.01.09; https://purl.org/pe-repo/ocde/ford#3.03.09

The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARSCoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSVB/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.